Mylan and Upjohn merger will create a new entity: Viatris
pharmafile | November 13, 2019 | News story | Manufacturing and Production, Research and Development, Sales and Marketing | Mylan, Pfizer, Upjohn, Viatris, pharma
The name for the new company emerging out of the merger between Pharma firm Mylan and Pfizer division Upjohn has been revealed. The new entity will be known as Viatris, a name derived from Latin which is designed to covey its new goals in meeting the needs of patients around the world.
The name breaks down to ‘via’, meaning path, and ‘tris’, meaning three. According to the company, this represents its goal of “providing a path to three core goals”: to expand access to medicines, drive innovation to better meet patient needs, and establish itself as a trusted partner to the global healthcare community.
According to the company, Viatris will aim to “unite Upjohn’s strong leadership position in China and emerging markets with Mylan’s significant presence in the US and Europe”, enabling a “meaningfully expanded geographic reach for Viatris’ broad product portfolio and future pipeline”.
“We wanted a name that would differentiate our new company and clearly explain how we will be a champion for global health,” said Robert J Coury, Executive Chairman at the new company. “We are creating a company unlike any other – a company focused on building a more hopeful and sustainable healthcare journey, empowering patients to live healthier at every stage of life.”
Michael Goettler, Group President at Upjohn and Chief Executive Officer at Viatris, added: “The name Viatris communicates the strength of our companies’ combined heritage and our shared goal to provide the highest-quality medicines to the most patients possible. We have an opportunity to deliver better health, better care and better value for patients and partners around the world.”
The name Viatris will come into effect once the merger of the two constituent companies comes to a close, which is expected mid-next year, until which point both entities will continue to operate as individual firms.
Matt Fellows
Related Content
Viatris and Idorsia enter research and development collaboration
Viatris and Idorsia have announced that they have entered into agreements for a significant global …
Pfizer’s Velsipity approved by EC for ulcerative colitis treatment
Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Velsipity (etrasimod) …
EC approves Pfizer’s Elrexfio for relapsed and refractory multiple myeloma
Pfizer has announced that the European Commission (EC) has granted conditional marketing authorisation for Elrexfio …
